Atossa Therapeutics, Inc. (ATOS)

Market Cap	121.23M
Revenue (ttm)	n/a
Net Income (ttm)	-26.34M
Shares Out	129.17M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	971,510
Open	0.8900
Previous Close	0.8879
Day's Range	0.8800 - 0.9638
52-Week Range	0.5526 - 1.6600
Beta	0.91
Analysts	Strong Buy
Price Target	6.17 (+557.43%)
Earnings Date	Aug 11, 2025

About ATOS

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2012
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: ATOS
• Website: https://www.atossatherapeutics.com

Analyst Summary

According to 3 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price target is $6.17, which is an increase of 557.43% from the latest price.

Price Target

$6.17

(557.43% upside)

Analyst Consensus: Strong Buy